NRG BR004 Paclitaxel, Trastuzumab, and Pertuzumab with or without Atezolizumab in Treating Patients with Metastatic Breast Cancer - Mercy Medical Center

NRG BR004 Paclitaxel, Trastuzumab, and Pertuzumab with or without Atezolizumab in Treating Patients with Metastatic Breast Cancer

Posted on: January 30, 2020

This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab is a form of “targeted therapy” because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system. Monoclonal antibodies, such as pertuzumab, may interfere with the ability of cancer cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab may kill more tumor cells. Eligibility includes being at least 18 years old and:

•Histologically confirmed adenocarcinoma of the breast with locally recurrent, unresectable disease or metastatic disease

•Patients must have metastatic disease

Disease must have been determined to be HER2-positive

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center